ArticleInternational journal of clinical pharmacy2025
Explanation and elaboration of MedinAI: guidelines for reporting artificial intelligence studies in medicines, pharmacotherapy, and pharmaceutical services.
Article in International journal of clinical pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- AI-generated patient information leaflets for oral anticoagulants: quality, usability, readability, and reproducibility compared with FDA-referenced materials.International journal of clinical pharmacy · 2026Article
- Advocating for trust in and trustworthy AI to transform evidence synthesis.Environmental evidence · 2025Article
- Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool.International journal of clinical pharmacy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The increasing adoption of artificial intelligence (AI) in medicines, pharmacotherapy, and pharmaceutical services necessitates clear guidance on reporting standards. While the MedinAI Statement (Bottacin in Int J Clin Pharm, https://doi.org/10.1007/s11096-025-01905-3, 2025) provides core guidelines for reporting AI studies in these fields, detailed explanations and practical examples are crucial for optimal implementation. This companion document was developed to offer comprehensive guidance and real-world examples for each guideline item. The document elaborates on all 14 items and 78 sub-items across four domains: core, ethical considerations in medication and pharmacotherapy, medicines as products, and services related to medicines and pharmacotherapy. Through clear, actionable guidance and diverse examples, this document enhances MedinAI's utility, enabling researchers and stakeholders to improve the quality and transparency of AI research reporting across various contexts, study designs, and development stages.
Indexed as
Identifiers
40249526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.